Success Metrics

Clinical Success Rate
100.0%

Based on 19 completed trials

Completion Rate
100%(19/19)
Active Trials
8(24%)
Results Posted
16%(3 trials)

Phase Distribution

Ph not_applicable
3
9%
Ph phase_2
11
32%
Ph early_phase_1
8
24%
Ph phase_1
10
29%
Ph phase_3
1
3%

Phase Distribution

18

Early Stage

11

Mid Stage

1

Late Stage

Phase Distribution33 total trials
Early Phase 1First-in-human
8(24.2%)
Phase 1Safety & dosage
10(30.3%)
Phase 2Efficacy & side effects
11(33.3%)
Phase 3Large-scale testing
1(3.0%)
N/ANon-phased studies
3(9.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

90.5%

19 of 21 finished

Non-Completion Rate

9.5%

2 ended early

Currently Active

8

trials recruiting

Total Trials

34

all time

Status Distribution
Active(12)
Completed(19)
Terminated(2)
Other(1)

Detailed Status

Completed19
Recruiting8
Not yet recruiting3
Withdrawn2
Enrolling by invitation1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
34
Active
8
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 18 (24.2%)
Phase 110 (30.3%)
Phase 211 (33.3%)
Phase 31 (3.0%)
N/A3 (9.1%)

Trials by Status

completed1956%
enrolling_by_invitation13%
not_yet_recruiting39%
recruiting824%
unknown13%
withdrawn26%

Recent Activity

8 active trials
Showing 5 of 34
not_yet_recruitingphase_2

MDMA Therapy in Veterans With PTSD

NCT07569159
withdrawnphase_1

The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD.

NCT03752918
not_yet_recruitingphase_2

MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers and First Responders

NCT05455996
completedphase_3

Epigenetics and MDMA-Assisted Psychotherapy for PTSD

NCT06189027
recruitingphase_2

MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other

NCT05584826
View all 34 trials

Clinical Trials (34)

Showing 20 of 34 trialsScroll for more
NCT07569159Phase 2

MDMA Therapy in Veterans With PTSD

Not Yet Recruiting
NCT03752918Phase 1

The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD.

Withdrawn
NCT05455996Phase 2

MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers and First Responders

Not Yet Recruiting
NCT06189027Phase 3

Epigenetics and MDMA-Assisted Psychotherapy for PTSD

Completed
NCT05584826Phase 2

MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other

Recruiting
NCT07555132Not Applicable

Circulating Oxytocin Changes in Response to MDMA vs. Placebo in Adult Patients With Autism Spectrum Disorder and Matched Healthy Controls

Not Yet Recruiting
NCT06066853Early Phase 1

MDMA-assisted Therapy for Fibromyalgia

Recruiting
NCT06683014Phase 2

MDMA in Borderline Personality Disorder

Recruiting
NCT05746572Phase 2

MDMA Plus Exposure Therapy for PTSD

Enrolling By Invitation
NCT04060108

Stanford Regulating Circuits of the Brain Study - MDMA

Completed
NCT06989957Phase 1

Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)

Recruiting
NCT05138068Phase 2

Social Anxiety MDMA-Assisted Therapy Investigation

Completed
NCT05837845Phase 2

MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder

Recruiting
NCT05961527Phase 1

Group MDMA-therapy for Veterans With PTSD

Completed
NCT02876172Phase 1

MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD

Completed
NCT06353282Phase 2

MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents

Withdrawn
NCT06789705Not Applicable

Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls

Recruiting
NCT05943665Phase 2

MDMA for AUD/PTSD Comorbidity

Recruiting
NCT04053036Early Phase 1

Effects of Drugs on Responses to Brain and Emotional Processes

Completed
NCT05067244Phase 2

A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD)

Completed

Drug Details

Intervention Type
DRUG
Total Trials
34